Management of menopause in women with breast cancer

References

• Hewitt M, Greenfield S, Stovall E, eds. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: National Academies Press, 2006
   Google Scholar
• Sukumvanich P, Case LD, Van Zee K, et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer 2010;116:3102–11
   PubMed Web of Science ®Google Scholar
• Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Can Inst 2012;104:386–405
   PubMed Web of Science ®Google Scholar
• Bell RJ, Fradkin P, Schwarz M, Davis SR. Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis. Menopause 2013;20:15–21
   PubMed Web of Science ®Google Scholar
• Sayakhot P, Teede HJ, Gibson-Helm M, Vincent A. Differences in clinician understanding and management of early menopause after breast cancer. Climacteric 2013;16:479–89
   PubMed Web of Science ®Google Scholar
• Hickey M, Saunders C, Partridge A, et al. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol 2008;19:1669–80
   PubMed Web of Science ®Google Scholar
• Brunner RL, Aragaki A, Barnabei V, et al. Menopausal symptom experience before and after stopping estrogen therapy in the Women’s Health Initiative randomized, placebo-controlled trial. Menopause 2010;17:946–54
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996;348:1189–96
   PubMed Web of Science ®Google Scholar
• Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 2008;107:167–80
   PubMed Web of Science ®Google Scholar
• Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509–18
   PubMed Web of Science ®Google Scholar
• Powles TJ. Anti-oestrogenic prevention of breast cancer – the make or break point. Nat Rev Cancer 2002;2:787–94
   PubMed Web of Science ®Google Scholar
• Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006;24:1045–51
   PubMed Web of Science ®Google Scholar
• Zhao J, Liu J, Chen K, et al. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Res Treat 2014;145:113–28
   PubMed Web of Science ®Google Scholar
• Gupta P, Sturdee DW, Palin SL, et al. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric 2006;9:49–58
   PubMed Web of Science ®Google Scholar
• Marino JL, Saunders CM, Emery LI, et al. Nature and severity of menopausal symptoms and their impact on quality of life and sexual function in cancer survivors compared with women without a cancer history. Menopause 2014;21:267–74
   PubMed Web of Science ®Google Scholar
• Davis SR, Panjari M, Robinson PJ, Fradkin P, Bell RJ. Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis. Menopause 2014;21:1075–81
   PubMed Web of Science ®Google Scholar
• Sayakhot P, Vincent A, Deeks A, Teede H. Potential adverse impact of ovariectomy on physical and psychological function of younger women with breast cancer. Menopause 2011;18:786–93
   PubMed Web of Science ®Google Scholar
• Couzi R, Helzlsouer K, Fetting J. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 1995;13:2737–44
   PubMed Web of Science ®Google Scholar
• Carpenter JS, Andrykowski MA, Cordova M, et al. Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life. Cancer 1998;82:1682–91
   PubMed Web of Science ®Google Scholar
• Rand KL, Otte JL, Flockhart D, et al. Modeling hot flushes and quality of life in breast cancer survivors. Climacteric 2011;14:171–80
   PubMed Web of Science ®Google Scholar
• Archer DF, Sturdee DW, Baber R, et al. Menopausal hot flushes and night sweats: where are we now? Climacteric 2011;14:515–28
   PubMed Web of Science ®Google Scholar
• Vincent A, Ranasinha S, Sayakhot P, et al. Sleep difficulty mediates effects of vasomotor symptoms on mood in younger breast cancer survivors. Climacteric 2014;17:598–604
   PubMed Web of Science ®Google Scholar
• Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888–902
   PubMed Web of Science ®Google Scholar
• Ganz PA, Rowland JH, Desmond K, et al. Life after breast cancer: understanding women’s health-related quality of life and sexual functioning. J Clin Oncol 1998;16:501–14
   PubMed Web of Science ®Google Scholar
• Baumgart J, Nilsson K, Stavreus-Evers A, et al. Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. Am J Obstet Gynecol 2011;204:26.e1–7
   PubMed Web of Science ®Google Scholar
• Crandall C, Petersen L, Ganz PA, Greendale GA. Association of breast cancer and its therapy with menopause-related symptoms. Menopause 2004;11:519–30
   PubMed Web of Science ®Google Scholar
• Ganz PA, Rowland JH, Meyerowitz BE, Desmond KA. Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res 1998; 152:396–411
   PubMedGoogle Scholar
• Fallowfield L, Cella D, Cuzick J, et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004;22:4261–71
   PubMed Web of Science ®Google Scholar
• Panjari M, Bell RJ, Davis SR. Sexual function after breast cancer. J Sex Med 2011;8:294–302
   PubMed Web of Science ®Google Scholar
• Fooladi E, Bell RJ, Davis SR. Management strategies in SSRI-associated sexual dysfunction in women at midlife. Climacteric 2012;15:306–16
   PubMed Web of Science ®Google Scholar
• Fallowfield LJ, Kilburn LS, Langridge C, et al. Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. Br J Cancer 2012;106:1062–7
   PubMed Web of Science ®Google Scholar
• Ganz PA, Desmond KA, Leedham B, et al. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 2002;94:39–49
   PubMed Web of Science ®Google Scholar
• Bardia A, Arieas ET, Zhang Z, et al. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat 2012;131:907–14
   PubMed Web of Science ®Google Scholar
• Vance V, Mourtzakis M, McCargar L, Hanning R. Weight gain in breast cancer survivors: prevalence, pattern and health consequences. Obes Rev 2011;12:282–94
   PubMed Web of Science ®Google Scholar
• Bovelli D, Plataniotis G, Roila F, et al. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 2010;21(Suppl 5):v277–82
   PubMed Web of Science ®Google Scholar
• Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011;103:1299–309
   PubMed Web of Science ®Google Scholar
• Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265–79
   PubMed Web of Science ®Google Scholar
• Patnaik JL, Byers T, DiGuiseppi C, et al. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 2011;13:R64
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Body JJ, Brandi ML, et al. Cancer-associated bone disease. Osteoporos Int 2013;24:2929–53
   PubMed Web of Science ®Google Scholar
• Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008;19:1407–16
   PubMed Web of Science ®Google Scholar
• Neuhouser ML, Sorensen B, Hollis BW, et al. Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. Am J Clin Nutr 2008;88:133–9
   PubMed Web of Science ®Google Scholar
• Rada G, Capurro D, Pantoja T, et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2010;CD004923
   PubMed Web of Science ®Google Scholar
• Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta- analysis. JAMA 2006;295:2057–71
   PubMed Web of Science ®Google Scholar
• Shams T, Firwana B, Habib F, et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med 2014;29:204–13
   PubMed Web of Science ®Google Scholar
• L’Esperance S, Frenette S, Dionne A, Dionne JY. Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Supp Care Cancer 2013;21:1461–74
   PubMed Web of Science ®Google Scholar
• Markes M, Brockow T, Resch K. Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev 2009;CD005001
   Web of Science ®Google Scholar
• Daley A, Stokes-Lampard H, MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2011;CD006108
   Web of Science ®Google Scholar
• Thurston RC, Ewing LJ, Low CA, et al. Behavioral weight loss for the management of menopausal hot flashes: a pilot study. Menopause 2015;22:59–65
   PubMed Web of Science ®Google Scholar
• Bardia A, Novotny P, Sloan J, et al. Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis. Menopause 2009;16:477–83
   PubMed Web of Science ®Google Scholar
• Wyrwich KW, Spratt DI, Gass M, et al. Identifying meaningful differences in vasomotor symptoms among menopausal women. Menopause 2008;15:698–705
   PubMed Web of Science ®Google Scholar
• Joffe H, Guthrie KA, LaCroix AZ, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med 2014;174:1058–66
   PubMed Web of Science ®Google Scholar
• Reddy SY, Warner H, Guttuso T Jr, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006;108:41–8
   PubMed Web of Science ®Google Scholar
• Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004;291:1610–20
   PubMed Web of Science ®Google Scholar
• MacLennan Alastair H, Broadbent Jessica L, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;CD002978
   Google Scholar
• Richardson MK. Alternatives to hormone therapy for hot flashes: many choices but science is lacking. Menopause 2013;20:980–2
   PubMed Web of Science ®Google Scholar
• Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010;340:c693
   PubMed Web of Science ®Google Scholar
• Nunez GR, Pinczowski H, Zanellato R, et al. Bupropion for control of hot flashes in breast cancer survivors: a prospective, double-blind, randomized, crossover, pilot phase II trial. J Pain Symptom Manage 2013;45:969–79
   PubMed Web of Science ®Google Scholar
• Greenlee H, Kwan ML, Ergas IJ, et al. Complementary and alternative therapy use before and after breast cancer diagnosis: the Pathways Study. Breast Cancer Res Treat 2009;117:653–65
   PubMed Web of Science ®Google Scholar
• Nedrow A, Miller J, Walker M, et al. Complementary and alternative therapies for the management of menopause-related symptoms. a systematic evidence review. Arch Intern Med 2006;166:1453–65
   PubMed Web of Science ®Google Scholar
• Newton KM, Reed SD, LaCroix AZ, et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006;145:869–79
   PubMed Web of Science ®Google Scholar
• Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol 2012;13:309–18
   PubMed Web of Science ®Google Scholar
• Duijts SFA, van Beurden M, Oldenburg HSA, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol 2012;30:4124–33
   PubMed Web of Science ®Google Scholar
• Elkins G, Marcus J, Stearns V, et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol 2008;26:5022–6
   PubMed Web of Science ®Google Scholar
• Elkins GR, Fisher WI, Johnson AK, et al. Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial. Menopause 2013;20:291–8
   PubMed Web of Science ®Google Scholar
• Dodin S, Blanchet C, Marc I, et al. Acupuncture for menopausal hot flushes. Cochrane Database Syst Rev 2013;CD007410
   PubMed Web of Science ®Google Scholar
• Garcia MK, McQuade J, Haddad R, et al. Systematic review of acupuncture in cancer care: a synthesis of the evidence. J Clin Oncol 2013;31:952–60
   PubMed Web of Science ®Google Scholar
• Park H, Parker GL, Boardman CH, et al. A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients. Support Care Cancer 2011;19: 859–63
   PubMed Web of Science ®Google Scholar
• Gaweesh SS, Abdel-Gawad MMM, Nagaty AM, Ewies AAA. Folic acid supplementation may cure hot flushes in postmenopausal women: a prospective cohort study. Gynecol Endocrinol 2010;26:658–62
   PubMed Web of Science ®Google Scholar
• Carson JW, Carson KM, Porter LS, et al. Yoga of Awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial. Support Care Cancer 2009;17:1301–9
   PubMed Web of Science ®Google Scholar
• Panjari M, Davis SR. DHEA for postmenopausal women: a review of the evidence. Maturitas 2010;66:172–9
   PubMed Web of Science ®Google Scholar
• Lethaby A, Marjoribanks J, Kronenberg F, et al. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev 2013:CD001395
   Web of Science ®Google Scholar
• de Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316–37
   PubMed Web of Science ®Google Scholar
• Walega DR, Rubin LH, Banuvar S, et al. Effects of stellate ganglion block on vasomotor symptoms: findings from a randomized controlled clinical trial in postmenopausal women. Menopause 2014;21:807–14
   PubMed Web of Science ®Google Scholar
• Vincent A, Burger HG. Menopause and hormone replacement therapy. In Gershenson D, ed. Gynecologic Cancer: Controversies in Management. Edinburgh: Elsevier Churchill Livingstone, 2004:795–817
   Google Scholar
• Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453–5
   PubMed Web of Science ®Google Scholar
• von Schoultz E, Rutqvist LE, Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 2005; 97:533–5
   PubMed Web of Science ®Google Scholar
• Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009;10:135–46
   PubMed Web of Science ®Google Scholar
• Sismondi P, Kimmig R, Kubista E, et al. Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients – data from LIBERATE trial. Maturitas 2011;70:365–72
   PubMed Web of Science ®Google Scholar
• Fahlen M, Wallberg B, von Schoultz E, et al. Health-related quality of life during hormone therapy after breast cancer: a randomized trial. Climacteric 2011;14:164–70
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353–68
   PubMed Web of Science ®Google Scholar
• Suckling Jane A, Kennedy R, Lethaby A, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006:CD001500
   Web of Science ®Google Scholar
• Lee Y-K, Chung HH, Kim JW, et al. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstet Gynecol 2011;117:922–7
   PubMed Web of Science ®Google Scholar
• Biglia N, Peano E, Sgandurra P, et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 2010;26:404–12
   PubMed Web of Science ®Google Scholar
• Wills S, Ravipati A, Venuturumilli P, et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract 2012;8:144–8
   PubMedGoogle Scholar
• Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006;17:584–7
   PubMed Web of Science ®Google Scholar
• Moegele M, Buchholz S, Seitz S, Ortmann O. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Arch Gynecol Obstet 2012;285:1397–402
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793–802
   PubMed Web of Science ®Google Scholar
• Lappano R, Rosano C, De Marco P, et al. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Molec Cell Endocrinol 2010;320:162–70
   PubMed Web of Science ®Google Scholar
• Donders G, Neven P, Moegele M, et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat 2014; 145:371–9
   PubMed Web of Science ®Google Scholar
• Pfeiler G, Glatz C, Konigsberg R, et al. Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric 2011;14:339–44
   PubMed Web of Science ®Google Scholar
• Witherby S, Johnson J, Demers L, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist 2011;16:424–31
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Bachmann GA, Koninckx PR, et al. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2014;17:173–82
   PubMed Web of Science ®Google Scholar
• Wurz GT, Soe LH, DeGregorio MW. Ospemifene, vulvovaginal atrophy, and breast cancer. Maturitas 2013;74:220–5
   PubMed Web of Science ®Google Scholar
• Reed SD, Newton KM, LaCroix AZ, et al. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo- controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. Menopause 2008;15: 51–8
   PubMed Web of Science ®Google Scholar
• Krychman ML, Katz A. Breast cancer and sexuality: multi-modal treatment options. J Sex Med 2012;9:5–13
   PubMed Web of Science ®Google Scholar
• Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 2005;CD004509
   PubMed Web of Science ®Google Scholar
• Barton DL, Wender DB, Sloan JA, et al. Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido. J Natl Cancer Inst 2007;99: 672–9
   PubMed Web of Science ®Google Scholar
• Walker EM, Rodriguez AI, Kohn B, et al. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 2010;28:634–40
   PubMed Web of Science ®Google Scholar
• Davis SR. The effects of tibolone on mood and libido. Menopause 2002;9:162–70
   PubMed Web of Science ®Google Scholar
• Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update: a guideline from the American Heart Association. Circulation 2011;123:1243–62
   PubMed Web of Science ®Google Scholar
• Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S49–73
   PubMed Web of Science ®Google Scholar
• Coleman R, Body JJ, Aapro M, et al. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2014;25(Suppl 3):124–37
   Web of Science ®Google Scholar
• Mauri D, Valachis A, Polyzos IP, et al. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat 2009;116: 433–9
   PubMed Web of Science ®Google Scholar
• Eisen A, Trudeau M, Shelley W, et al. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat Rev 2008;34: 157–74
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol 2009;27:2831–7
   PubMed Web of Science ®Google Scholar
• Ensrud KE, Joffe H, Guthrie KA, et al. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. Menopause 2012; 19:848–55
   PubMed Web of Science ®Google Scholar
• LaCroix AZ, Freeman EW, Larson J, et al. Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: A randomized controlled trial. Maturitas 2012;73:361–8
   PubMed Web of Science ®Google Scholar
• Speroff L, Gass M, Constantine G, Olivier S. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77–87
   PubMed Web of Science ®Google Scholar